Advanced Blends
GLOW (BPC-157 + TB-500 + GHK-Cu)
← Back to Library
Site-only / unverified FDA safety flag Site-only / unverified Aesthetics Repair
Educational reference only. Read the full disclaimer.
The protocols below are not automatically an FDA-approved or clinically verified regimen unless
explicitly marked as label-verified or clinical-trial above.
Overview
Route(s): Subcutaneous
Typical vial sizes: 70 mg
Dosing window: Anytime
Receptor / target: VEGFR2; G-Actin; MMP
Properties: Dopamine Buffer
Pre-mixed: No
Site-sourced protocols
Standard Protocol
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-12 | 2.8mg daily | Yields exactly 2.0mg GHK-Cu, 400mcg BPC-157, and 400mcg TB-500. Protocol is strictly 5 days on, 2 days off (skip weekends) to prevent copper toxicity. |
Site-provided protocol; not independently verified as label dosing unless graded otherwise on this page.
Alternative: Low/Slow Maintenance
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-12 | 1.4mg daily | Yields 1.0mg GHK-Cu, 200mcg BPC, 200mcg TB. 5 days on, 2 days off. Ideal for long-term anti-aging without heavy copper accumulation. |
Site-provided alternative protocol; not an approved-label regimen unless graded otherwise on this page.
Protocol logic check
Protocol context: Blend protocols have to pass every ingredient's logic, not just the headline goal. If one ingredient conflicts with a condition, medication, or selected compound, the blend recommendation changes. Entry context: target (VEGFR2; G-Actin; MMP); route Subcutaneous; timing Anytime. Site-only/low dosing tables are hypotheses, not recommendations. FDA/safety flags lower confidence and raise the evidence bar for any claimed benefit. Compatibility is conditional: a reasonable solo compound can become inappropriate once a contraindicated partner is added. For blends, the highest-risk ingredient sets the caution level.
Independent evidence
Independent safety notes: No approved-label dosing was identified for this combined blend. | FDA lists BPC-157 among withdrawn nominated bulk substances with potential significant safety risks and limited safety information for proposed routes. | FDA lists TB-500 (thymosin beta-4 fragment LKKTETQ) among withdrawn nominated bulk substances with no identified human exposure data. | FDA lists injectable GHK-Cu among withdrawn nominated bulk substances with limited human safety data.
Regulatory status: not approved multi compound blend component warnings
Storage
No independently verified storage guidance found. Treat any site-sourced storage claim as unverified, and see the general storage guidance in the FAQ.
Contraindications (site-sourced)
- Active cancer: BPC-157's potent angiogenic (VEGFR2-mediated) activity and GHK-Cu's comprehensive pro-growth gene program upregulation are both directly contraindicated in the context of active malignancy; tumor angiogenesis (the growth of new blood vessels into tumor tissue, upon which solid tumor growth above 1-2mm depends) would be accelerated by BPC-157's VEGFR2 stimulation; GHK-Cu's upregulation of collagen production, cell proliferation, and growth factor signaling could support tumor stroma formation and growth; absolute contraindication. Site-only / unverified
- Zinc deficiency (serum zinc below reference range): GHK-Cu is a copper-supplying compound; copper and zinc compete for intestinal absorption through shared ZIP/ZnT transporter systems (Menkes-Wilson competitive transport); daily GHK-Cu administration progressively depletes zinc by outcompeting zinc for intestinal absorption and increasing metallothionein-mediated zinc sequestration; zinc deficiency at baseline is a contraindication to initiating GLOW; zinc status should be confirmed and repleted before starting any GLOW cycle, and zinc supplementation (15-30mg/day zinc bisglycinate or zinc picolinate) is required throughout all GLOW cycles. Site-only / unverified
- Wilson's disease (copper metabolism disorder): Wilson's disease causes pathological copper accumulation due to defective ATP7B copper exporter function; GHK-Cu's copper delivery is absolutely contraindicated in Wilson's disease. Site-only / unverified
- Active inflammatory bowel disease in severe flare: while BPC-157 has mucosal protective effects in IBD, the high-dose GHK-Cu component's copper delivery in the context of the compromised gut mucosa and altered metal absorption of severe IBD flares is not characterized; GLOW is appropriate for remission maintenance and does not cover acute severe flare management. Site-only / unverified
- Concurrent copper-supplementing medications or multi-mineral supplements with high copper content: additive copper load from exogenous copper sources during a GLOW cycle could exceed safe copper accumulation thresholds; total daily copper intake across all sources should be monitored. Site-only / unverified
- Known hypersensitivity to BPC-157 (pentadecapeptide), TB-500 (thymosin beta-4 fragment), GHK-Cu (copper tripeptide), or formulation excipients. Site-only / unverified
- Severe hepatic impairment: the liver is the primary organ for copper processing and biliary copper excretion; compromised hepatic copper handling in cirrhosis or severe hepatic disease could lead to copper accumulation even with the 5-days-on protocol. Site-only / unverified
- Pregnancy: the combined angiogenic, matrix remodeling, and copper-delivering activity of GLOW during pregnancy has not been evaluated; both BPC-157 and GHK-Cu have effects on vascular and connective tissue remodeling that overlap with the highly active vascular and matrix changes of normal pregnancy. Site-only / unverified
- History of copper toxicity (symptoms of nausea, vomiting, abdominal pain, elevated LFTs from previous copper exposure): previous sensitivity to copper loading suggests heightened risk of accumulation on the GLOW copper load. Site-only / unverified
Side effects (site-sourced)
- Injection site pain (PIP): even within the blended formulation, GHK-Cu contributes some degree of injection site pain beyond standard peptide injections; typically manageable and significantly reduced versus standalone GHK-Cu at equivalent doses; the GLOW blend formulation's primary design purpose is to mitigate this effect. Site-only / unverified
- Lethargy and sedation following injection: primarily attributable to the BPC-157 and TB-500 components; the mechanism is dopaminergic modulation; typically mild and lasting 1-3 hours post-injection; the "Dopamine Buffer" property tag reflects this CNS dopamine system interaction. Site-only / unverified
- Zinc depletion: the most important monitoring parameter; progressive zinc depletion from GHK-Cu copper competition occurs across all GLOW cycles; manifestations include impaired immune function, hair thinning, delayed wound healing, and taste/smell changes; zinc supplementation is essential. Site-only / unverified
- Mild copper accumulation symptoms: at doses approaching toxicity (unlikely at standard GLOW protocol doses with the 5-days-on schedule, but possible with protocol violations): nausea, vomiting, metallic taste, abdominal discomfort; the 5-days-on/2-days-off and 8-12 week cycle limit prevent clinically significant copper accumulation at standard doses. Site-only / unverified
- Mild headache: occasionally reported in the first 1-2 weeks of a GLOW cycle; mechanism unclear but possibly related to the hemodynamic effects of BPC-157's NO-synthase activity and vascular changes. Site-only / unverified
- Elevated liver enzymes (ALT/AST): mild transient LFT elevation occasionally observed during GLOW cycles, particularly at the 2.0mg GHK-Cu daily dose; related to hepatic copper processing load; typically resolves with cycle cessation and washout; warrants monitoring in subjects with pre-existing liver conditions. Site-only / unverified
- Temporary increase in existing inflammation signals: as the repair cascade activates, the initial phase can produce transient mild increases in local inflammation before anti-inflammatory and repair phases predominate; most notable in subjects using GLOW for acute injury management. Site-only / unverified
- Anhedonia (rare): occasionally reported with the BPC-157/TB-500 combination; related to the dopaminergic modulation mechanism of BPC-157; typically mild and transient. Site-only / unverified
Compatibility
The relationships below come from the source site's internal engine and were not verified independently. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.
Reported synergistic:
Reported contraindicated combinations:
BPC-157TB-500 (Thymosin Beta-4)GHK-Cu (Copper Tripeptide-1)KLOW (BPC-157 + TB-500 + KPV + GHK-Cu)tri-heal-blend